LUGPA’s Position on PSA Screening

LUGPA’s Position on PSA Screening

The Large Urology Group Practice Association (LUGPA), an organization advocating for integrated and coordinated urological care with more than 2,000 physician experts across the U.S., has been carefully monitoring the recent controversy surrounding the use of prostate-specific antigen (PSA) testing for early detection of prostate cancer. Despite high-level evidence for the use of PSA testing as a screening tool and its role as a predictor of future risk, several conflicting guideline statements have been released from various organizations. After careful evaluation of previously published guidelines as well as thorough review of recent statements from the European Association of Urology and the World Prostate Cancer Congress, the LUGPA adopted an official position on PSA screening.

Listen to Dr. Deepak A. Kapoor, President of LUGPA and Chairman and CEO of Integrated Medical Professionals, PLLC, describe LUGPA’s position on PSA screening in an exclusive slide lecture for UroToday.

Deepak A. Kapoor BIO

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.